Knockout of SHP2 by CRISPR/Cas9 in cancer cells enhanced the expression of MHC class I and PD-L1 proteins in cancer cells through IFN-γ signaling and enhanced the response against PD-1 blockade in cogene mouse models (37). This evidence concerns the gene PTPN11 and cancer.